Gilead Sciences, Inc.

1477 articles with Gilead Sciences, Inc.

• 

  Ka-ching! Gilead Ends Year With Two Major Deals That Could Total More Than $3.125 Billion

  12/20/2018

  Gilead Sciences, in two days, inked two collaboration deals with two different companies that could pay out an aggregate of more than $3.125 billion. One of those deals is in the area of immuno-oncology, the other in fibrosis.

• Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases

  12/19/2018

  Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases.

• 

  BioSpace Movers and Shakers: Dec. 17

  12/17/2018

  With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.
• 

  Big Drug Launches Have Taught Drug Companies Some Important Lessons

  12/11/2018

  With the closure of another year just weeks ahead, this time of year is one that many people use to take a look behind and see what lessons were learned over the past 12 months. For the world of biopharma, it’s also important to see what lessons have been learned.

• Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer

  12/10/2018

  Mr. O’Day Brings Global Pharmaceutical Leadership Experience Across Geographies and Therapeutic Areas

• 

  Gilead Taps Roche Veteran Daniel O’Day as New CEO

  12/10/2018

  Gilead Sciences officially announced that long-time Roche veteran, Daniel O’Day, will assume the helm of the company as chairman and chief executive officer beginning March 1. O'Day takes over for John Milligan, who announced his plans to retire by the end of the year in July.
• 

  FDA Approves NIH-Funded Genetic Database, Issues Draft Guidance on NASH

  12/5/2018

  The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.

• China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

  12/4/2018

  Fixed-Dose Combination HIV Treatment Backbone Can Be Paired with Range of Third Agents

• 

  A Look at a Few ASH Highlights: Gilead/Kite, Novartis, Celgene, Bluebird Bio, Seattle Genetics

  12/3/2018

  The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today.
• 

  Are Gilead or Roche Interested in Buying Tesaro? Company Rumored to Be on the Market

  11/19/2018

  Tesaro, located in Waltham, Mass., is rumored to be up for sale. The rumors caused shares to rocket as much as 39 percent on Friday, but it’s not the first time rumors have floated that the company might be on the auction block.

• Hilliard Martinez Gonzales LLP: Gilead Sued For Intentionally Withholding Safer HIV Drug

  11/17/2018

  Today Bob Hilliard filed a lawsuit against Gilead, claiming the giant drug company intentionally kept a safer HIV drug from hundreds of thousands of patients so as to protect its multi-billion dollar patent on a less safe drug.

• 

  AbbVie’s Mavyret Demonstrates Sky-High Cure Rates in Hepatitis C

  11/14/2018

  Chicago-based AbbVie just announced new data for its Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.

• Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27

  11/12/2018

  Webcast Available Through Gilead Corporate Website

• 

  As Deadliest Strain Ravages Country, Four Experimental Ebola Vaccines to Be Deployed in the Congo

  11/12/2018

  As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials has taken four experimental vaccines to the front lines and begun to administer it to patients who may have been exposed to the deadly virus.

• Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018

  11/9/2018

  Data Demonstrate Sofosbuvir-Based Regimens Achieve High Cure Rates in Hepatitis C Patient Populations with Unmet Need

• Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018

  11/9/2018

  Phase 2 Data Presented on Investigational FXR Agonist GS-9674 in NASH

• Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018

  11/9/2018

  GS-9674 Granted Orphan Drug Designation by the U.S. Food and Drug Administration

• Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018

  11/1/2018

  Data Reinforce Breadth of Cell Therapy Portfolio and Commitment to Continued Innovation for People with Advanced Cancers

• Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies

  10/31/2018

  Global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer.

• 

  It Takes Two: Gilead and Tango Partner on Immuno-Oncology

  10/31/2018

  The deal, which will last several years, has Tango performing target discovery and validation. Gilead will be able to option rights to up to five targets that come out of Tango’s work.